- Page 1: PHARMACEUTICAL MANUFACTURING HANDBO
- Page 5 and 6: PHARMACEUTICAL MANUFACTURING HANDBO
- Page 7 and 8: CONTRIBUTORS Susanna Abrahms é n -
- Page 9 and 10: CONTRIBUTORS vii Eddy Castellanos G
- Page 11 and 12: CONTENTS PREFACE xiii SECTION 1 MAN
- Page 13: CONTENTS xi 5.11 Transdermal Drug D
- Page 17: SECTION 1 MANUFACTURING SPECIALTIES
- Page 21 and 22: INTRODUCTION 5 provide a suffi cien
- Page 23 and 24: therapeutic potency, specifi city,
- Page 25 and 26: Diffi culties in peroral delivery h
- Page 27 and 28: tial. Therefore, the indication and
- Page 29 and 30: TABLE 2 Continued Parameter Assesse
- Page 31 and 32: ceutical stability program should a
- Page 33 and 34: FORMULATION DEVELOPMENT 17 see when
- Page 35 and 36: FORMULATION DEVELOPMENT 19 heat ter
- Page 37 and 38: organisms, stability (shelf life),
- Page 39 and 40: TABLE 3 Potential Degradative Mecha
- Page 41 and 42: QUALITY BY DESIGN AND SCALE-UP 25 w
- Page 43 and 44: QUALITY BY DESIGN AND SCALE-UP 27 p
- Page 45 and 46: ACKNOWLEDGMENTS The authors would l
- Page 47 and 48: REFERENCES 31 37. Berglund , M. , B
- Page 49 and 50: 1.2 REGULATORY CONSIDERATIONS IN AP
- Page 51 and 52: HISTORY OF BIOLOGICS REGULATION IN
- Page 53 and 54: HISTORY OF BIOLOGICS REGULATION IN
- Page 55 and 56: HISTORY OF BIOLOGICS REGULATION IN
- Page 57 and 58: TABLE 4 FDA Center Regulatory Respo
- Page 59 and 60: approved via a BLA under the PHSA a
- Page 61 and 62: LEGAL ARGUMENTS RELATED TO FOLLOW-O
- Page 63 and 64: SCIENTIFIC ISSUES RELATED TO FOLLOW
- Page 65 and 66: SCIENTIFIC ISSUES RELATED TO FOLLOW
- Page 67 and 68: albumin with polysorbate 80 and gly
- Page 69 and 70:
PROPOSED REGULATORY PARADIGM: CASE
- Page 71 and 72:
effi cacy for Genotropin. These dat
- Page 73:
REFERENCES 57 21. Webber , K. ( 200
- Page 76 and 77:
60 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 78 and 79:
62 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 80 and 81:
64 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 82 and 83:
66 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 84 and 85:
68 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 86 and 87:
70 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 88 and 89:
72 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 90 and 91:
74 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 92 and 93:
76 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 94 and 95:
78 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 96 and 97:
80 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 98 and 99:
82 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 100 and 101:
84 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 102 and 103:
86 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 104 and 105:
88 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 106 and 107:
90 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 108 and 109:
92 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 110 and 111:
94 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 112 and 113:
96 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 115 and 116:
2.1 STERILE PRODUCT MANUFACTURING J
- Page 117 and 118:
(FDA) in its 2004 Guideline on Ster
- Page 119 and 120:
PROCESS SELECTION AND DESIGN 103 di
- Page 121 and 122:
FACILITY DESIGN 105 is transfer int
- Page 123 and 124:
FACILITY DESIGN 107 The formulation
- Page 125 and 126:
FACILITY DESIGN 109 In large operat
- Page 127 and 128:
FACILITY DESIGN 111 universal expec
- Page 129 and 130:
FACILITY DESIGN 113 facilities equi
- Page 131 and 132:
from manual compounding of small ba
- Page 133 and 134:
2.1.5.4 Other Utilities The operati
- Page 135 and 136:
STERILIZATION AND DEPYROGENATION 11
- Page 137 and 138:
ENVIRONMENTAL CONTROL AND MONITORIN
- Page 139 and 140:
ENVIRONMENTAL CONTROL AND MONITORIN
- Page 141 and 142:
PRODUCTION ACTIVITIES 125 It is inc
- Page 143 and 144:
PRODUCTION ACTIVITIES 127 Filling o
- Page 145 and 146:
assembly/technique) using a growth
- Page 147 and 148:
culminate in the incubation of the
- Page 149 and 150:
REFERENCES REFERENCES 133 1. U.S. F
- Page 151:
ADDITIONAL READINGS 135 Ljungvist ,
- Page 155 and 156:
3.1 FROM PILOT PLANT TO MANUFACTURI
- Page 157 and 158:
BACKGROUND 141 Pisano [3] discusses
- Page 159 and 160:
T amb F3 F2 F1 Scale Scale Scale Ad
- Page 161 and 162:
LABORATORY VESSELS AND REACTION CAL
- Page 163 and 164:
LABORATORY VESSELS AND REACTION CAL
- Page 165 and 166:
Drive nozzle face D FIGURE 4 C E 10
- Page 167 and 168:
Overall U, English units 80 70 60 5
- Page 169 and 170:
mCp/UA, min 28 27 26 25 24 23 22 21
- Page 171 and 172:
control valve was on the inlet stre
- Page 173 and 174:
3.1.6 SUMMARY In this chapter we ha
- Page 175 and 176:
3.2 PACKAGING AND LABELING Maria In
- Page 177 and 178:
PACKAGING MATERIALS 161 For these r
- Page 179 and 180:
PACKAGING MATERIALS 163 3.2.2.2 Gla
- Page 181 and 182:
PACKAGING MATERIALS 165 Rubber clos
- Page 183 and 184:
PACKAGING MATERIALS 167 of the USP
- Page 185 and 186:
PACKAGING MATERIALS 169 Topical del
- Page 187 and 188:
PACKAGING MATERIALS 171 based topic
- Page 189 and 190:
QUALITY CONTROL OF PACKAGING MATERI
- Page 191 and 192:
QUALITY CONTROL OF PACKAGING MATERI
- Page 193 and 194:
TABLE 5 Chapter U.S. Pharmacopeia G
- Page 195 and 196:
QUALITY CONTROL OF PACKAGING MATERI
- Page 197 and 198:
Topical Drug Products Topical dosag
- Page 199 and 200:
IMPORTANCE OF PROPER PACKAGING AND
- Page 201 and 202:
4. Require that vials containing me
- Page 203 and 204:
8. A description of the scientifi c
- Page 205 and 206:
The only warning that is necessary,
- Page 207 and 208:
REGULATORY ASPECTS 191 Section 1451
- Page 209 and 210:
include any term qualifying a unit
- Page 211 and 212:
for the promulgation of any such re
- Page 213 and 214:
Label Issuance and Control • Acce
- Page 215 and 216:
REFERENCES 199 9. Aspinall , J. A.
- Page 217 and 218:
3.3 CLEAN - FACILITY DESIGN, CONSTR
- Page 219 and 220:
PLANNING FOR PROJECT SUCCESS 203 im
- Page 221 and 222:
PLANNING FOR PROJECT SUCCESS 205 of
- Page 223 and 224:
DESIGN OPTIONS 207 with clean - roo
- Page 225 and 226:
TABLE 1 Room Grade f A g B C D E An
- Page 227 and 228:
Clean Garment Storage Bench Air loc
- Page 229 and 230:
DESIGN OPTIONS 213 FIGURE 4 Furnish
- Page 231 and 232:
DESIGN OPTIONS 215 FIGURE 6 A CMU w
- Page 233 and 234:
DESIGN OPTIONS 217 spaces to suppor
- Page 235 and 236:
DESIGN OPTIONS 219 FIGURE 12 The wa
- Page 237 and 238:
DESIGN OPTIONS 221 FIGURE 15 Severa
- Page 239 and 240:
to the facility. IEST - RP - CC006
- Page 241 and 242:
CONSTRUCTION PHASE: CLEAN BUILD PRO
- Page 243 and 244:
APPENDIX A 227 and storage space fo
- Page 245 and 246:
APPENDIX A 229 closed at the neck,
- Page 247 and 248:
I. The HEPA fi lter protective fi l
- Page 249:
SECTION 4 NORMAL DOSAGE FORMS
- Page 252 and 253:
236 SOLID DOSAGE FORMS 4.1.9 Chewab
- Page 254 and 255:
238 SOLID DOSAGE FORMS A dose solub
- Page 256 and 257:
240 SOLID DOSAGE FORMS TABLE 3 Exci
- Page 258 and 259:
242 SOLID DOSAGE FORMS Antiadherent
- Page 260 and 261:
244 SOLID DOSAGE FORMS Despite the
- Page 262 and 263:
246 SOLID DOSAGE FORMS TABLE 4 Poly
- Page 264 and 265:
248 SOLID DOSAGE FORMS TABLE 5 Caps
- Page 266 and 267:
250 SOLID DOSAGE FORMS of both. Sof
- Page 268 and 269:
252 SOLID DOSAGE FORMS reaction in
- Page 270 and 271:
254 SOLID DOSAGE FORMS to a rapid o
- Page 272 and 273:
256 SOLID DOSAGE FORMS TABLE 8 Typi
- Page 274 and 275:
258 SOLID DOSAGE FORMS Piston Base
- Page 276 and 277:
260 SOLID DOSAGE FORMS TABLE 10 Exa
- Page 278 and 279:
262 SOLID DOSAGE FORMS pressures du
- Page 280 and 281:
264 SOLID DOSAGE FORMS 12. The Unit
- Page 283 and 284:
4.2 SEMISOLID DOSAGES: OINTMENTS, C
- Page 285 and 286:
OINTMENTS AND CREAMS 269 bases), ab
- Page 287 and 288:
OINTMENTS AND CREAMS 271 compendial
- Page 289 and 290:
TABLE 2 Properties of Different Gra
- Page 291 and 292:
OINTMENTS AND CREAMS 275 Preparatio
- Page 293 and 294:
OINTMENTS AND CREAMS 277 TABLE 3 Cr
- Page 295 and 296:
OINTMENTS AND CREAMS 279 FIGURE 1 S
- Page 297 and 298:
TABLE 4 Drug Acyclovir Alclometason
- Page 299 and 300:
OINTMENTS AND CREAMS 283 Packaging
- Page 301 and 302:
OINTMENTS AND CREAMS 285 presence o
- Page 303 and 304:
OINTMENTS AND CREAMS 287 side and s
- Page 305 and 306:
TABLE 6 a Drug Acyclovir Atropine s
- Page 307 and 308:
TABLE 7 Continued Commercial Produc
- Page 309 and 310:
GELS 293 (e.g., carbomers) that con
- Page 311 and 312:
GELS 295 molecular weight, gelling
- Page 313 and 314:
GELS 297 Ethylcellulose Ethylcellul
- Page 315 and 316:
GELS 299 practically insoluble in w
- Page 317 and 318:
GELS 301 out takes place. The visco
- Page 319 and 320:
GELS 303 FIGURE 3 Vacuum processing
- Page 321 and 322:
GELS 305 chramatograph for quantita
- Page 323 and 324:
TABLE 10 a Drug Benzocaine Benzoyl
- Page 325 and 326:
TABLE 11 Continued Type of Change C
- Page 327 and 328:
REFERENCES 311 8. Fisher , A. A. (
- Page 329 and 330:
4.3 LIQUID DOSAGE FORMS Maria V. Ru
- Page 331 and 332:
are both challenges and opportuniti
- Page 333 and 334:
GENERALITIES 317 that are more deci
- Page 335 and 336:
APPROACHES 319 To apply QbD as a sy
- Page 337 and 338:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 339 and 340:
Dosing Pumps Collector Tank Continu
- Page 341 and 342:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 343 and 344:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 345 and 346:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 347 and 348:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 349 and 350:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 351 and 352:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 353 and 354:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 355 and 356:
LIQUID DOSAGE FORMS 339 For Solutio
- Page 357 and 358:
Suspension, Extended Release A liqu
- Page 359 and 360:
REFERENCES 343 26. Guides to inspec
- Page 361:
SECTION 5 SPECIAL/NEW DOSAGE FORMS
- Page 364 and 365:
348 CONTROLLED-RELEASE DOSAGE FORMS
- Page 366 and 367:
350 CONTROLLED-RELEASE DOSAGE FORMS
- Page 368 and 369:
352 CONTROLLED-RELEASE DOSAGE FORMS
- Page 370 and 371:
354 CONTROLLED-RELEASE DOSAGE FORMS
- Page 372 and 373:
356 CONTROLLED-RELEASE DOSAGE FORMS
- Page 374 and 375:
358 CONTROLLED-RELEASE DOSAGE FORMS
- Page 376 and 377:
360 CONTROLLED-RELEASE DOSAGE FORMS
- Page 378 and 379:
362 CONTROLLED-RELEASE DOSAGE FORMS
- Page 380 and 381:
364 CONTROLLED-RELEASE DOSAGE FORMS
- Page 382 and 383:
366 CONTROLLED-RELEASE DOSAGE FORMS
- Page 384 and 385:
368 CONTROLLED-RELEASE DOSAGE FORMS
- Page 386 and 387:
370 CONTROLLED-RELEASE DOSAGE FORMS
- Page 388 and 389:
372 CONTROLLED-RELEASE DOSAGE FORMS
- Page 390 and 391:
374 CONTROLLED-RELEASE DOSAGE FORMS
- Page 392 and 393:
376 CONTROLLED-RELEASE DOSAGE FORMS
- Page 394 and 395:
378 CONTROLLED-RELEASE DOSAGE FORMS
- Page 396 and 397:
380 CONTROLLED-RELEASE DOSAGE FORMS
- Page 398 and 399:
382 CONTROLLED-RELEASE DOSAGE FORMS
- Page 400 and 401:
384 CONTROLLED-RELEASE DOSAGE FORMS
- Page 402 and 403:
386 CONTROLLED-RELEASE DOSAGE FORMS
- Page 404 and 405:
388 CONTROLLED-RELEASE DOSAGE FORMS
- Page 406 and 407:
390 CONTROLLED-RELEASE DOSAGE FORMS
- Page 408 and 409:
392 CONTROLLED-RELEASE DOSAGE FORMS
- Page 410 and 411:
394 BIODEGRADABLE POLYMER-BASED MIC
- Page 412 and 413:
396 BIODEGRADABLE POLYMER-BASED MIC
- Page 414 and 415:
398 BIODEGRADABLE POLYMER-BASED MIC
- Page 416 and 417:
400 BIODEGRADABLE POLYMER-BASED MIC
- Page 418 and 419:
402 BIODEGRADABLE POLYMER-BASED MIC
- Page 420 and 421:
404 BIODEGRADABLE POLYMER-BASED MIC
- Page 422 and 423:
406 BIODEGRADABLE POLYMER-BASED MIC
- Page 424 and 425:
408 BIODEGRADABLE POLYMER-BASED MIC
- Page 426 and 427:
410 BIODEGRADABLE POLYMER-BASED MIC
- Page 428 and 429:
412 BIODEGRADABLE POLYMER-BASED MIC
- Page 430 and 431:
414 BIODEGRADABLE POLYMER-BASED MIC
- Page 432 and 433:
416 BIODEGRADABLE POLYMER-BASED MIC
- Page 434 and 435:
418 BIODEGRADABLE POLYMER-BASED MIC
- Page 436 and 437:
420 BIODEGRADABLE POLYMER-BASED MIC
- Page 438 and 439:
422 BIODEGRADABLE POLYMER-BASED MIC
- Page 440 and 441:
424 BIODEGRADABLE POLYMER-BASED MIC
- Page 442 and 443:
426 BIODEGRADABLE POLYMER-BASED MIC
- Page 444 and 445:
428 BIODEGRADABLE POLYMER-BASED MIC
- Page 446 and 447:
430 BIODEGRADABLE POLYMER-BASED MIC
- Page 448 and 449:
432 BIODEGRADABLE POLYMER-BASED MIC
- Page 450 and 451:
434 BIODEGRADABLE POLYMER-BASED MIC
- Page 452 and 453:
436 BIODEGRADABLE POLYMER-BASED MIC
- Page 454 and 455:
438 BIODEGRADABLE POLYMER-BASED MIC
- Page 456 and 457:
440 BIODEGRADABLE POLYMER-BASED MIC
- Page 459 and 460:
5.3 LIPOSOMES AND DRUG DELIVERY Sop
- Page 461 and 462:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 463 and 464:
H 2 C O O O - O - - O P O - O P O O
- Page 465 and 466:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 467 and 468:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 469 and 470:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 471 and 472:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 473 and 474:
In the second approach (probe sonic
- Page 475 and 476:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 477 and 478:
O R1 SH + N R2 N R2 R 1 Anchor R 2
- Page 479 and 480:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 481 and 482:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 483 and 484:
IN VIVO DISTRIBUTION 467 marrow (du
- Page 485 and 486:
IN VIVO DISTRIBUTION 469 absorption
- Page 487 and 488:
% injected dose/g % injected dose/g
- Page 489 and 490:
IN VIVO DISTRIBUTION 473 combinatio
- Page 491 and 492:
IN VIVO DISTRIBUTION 475 delivery i
- Page 493 and 494:
IN VIVO DISTRIBUTION 477 increases
- Page 495 and 496:
IN VIVO DISTRIBUTION 479 TABLE 3 Ex
- Page 497 and 498:
IN VIVO DISTRIBUTION 481 As mention
- Page 499 and 500:
TABLE 4 Currently Marketed Liposome
- Page 501 and 502:
addition to those existing already,
- Page 503 and 504:
Survival (%) 100 75 50 25 APPLICATI
- Page 505 and 506:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 507 and 508:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 509 and 510:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 511 and 512:
μg C 6 / MI Blood Ng C 6 / mg Tumo
- Page 513 and 514:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 515 and 516:
DXR plasma concentration (μg/mL) 1
- Page 517 and 518:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 519 and 520:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 521 and 522:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 523 and 524:
REFERENCES 507 6. Allen , T. M. , a
- Page 525 and 526:
REFERENCES 509 42. LeNeveu , D. M.
- Page 527 and 528:
REFERENCES 511 78. Frederik , P. M.
- Page 529 and 530:
REFERENCES 513 115. Grit , M. , de
- Page 531 and 532:
REFERENCES 515 154. Maruyama , K. ,
- Page 533 and 534:
REFERENCES 517 185. Schnyder , A. ,
- Page 535 and 536:
REFERENCES 519 220. Gregoriadis , G
- Page 537 and 538:
REFERENCES 521 254. Shek , P. N. ,
- Page 539 and 540:
REFERENCES 523 290. Weiner , N. , W
- Page 541 and 542:
REFERENCES 525 328. Torres , P. F.
- Page 543 and 544:
REFERENCES 527 A. ( 2004 ), Human i
- Page 545 and 546:
REFERENCES 529 393. Fiorillo , A. ,
- Page 547 and 548:
REFERENCES 531 423. Paridaens , R.
- Page 549:
REFERENCES 533 455. Seiden , M. V.
- Page 552 and 553:
536 BIODEGRADABLE NANOPARTICLES 5.4
- Page 554 and 555:
538 BIODEGRADABLE NANOPARTICLES Som
- Page 556 and 557:
540 BIODEGRADABLE NANOPARTICLES for
- Page 558 and 559:
542 BIODEGRADABLE NANOPARTICLES ami
- Page 560 and 561:
544 BIODEGRADABLE NANOPARTICLES bot
- Page 562 and 563:
546 BIODEGRADABLE NANOPARTICLES Pol
- Page 564 and 565:
548 BIODEGRADABLE NANOPARTICLES 99m
- Page 566 and 567:
550 BIODEGRADABLE NANOPARTICLES ext
- Page 568 and 569:
552 BIODEGRADABLE NANOPARTICLES 5.4
- Page 570 and 571:
554 BIODEGRADABLE NANOPARTICLES 14.
- Page 572 and 573:
556 BIODEGRADABLE NANOPARTICLES 48.
- Page 574 and 575:
558 BIODEGRADABLE NANOPARTICLES Cal
- Page 576 and 577:
560 BIODEGRADABLE NANOPARTICLES cop
- Page 578 and 579:
562 BIODEGRADABLE NANOPARTICLES 150
- Page 580 and 581:
564 BIODEGRADABLE NANOPARTICLES of
- Page 582 and 583:
566 IN VITRO VALIDATION AND ORAL FO
- Page 584 and 585:
568 IN VITRO VALIDATION AND ORAL FO
- Page 586 and 587:
570 IN VITRO VALIDATION AND ORAL FO
- Page 588 and 589:
572 IN VITRO VALIDATION AND ORAL FO
- Page 590 and 591:
574 IN VITRO VALIDATION AND ORAL FO
- Page 592 and 593:
576 IN VITRO VALIDATION AND ORAL FO
- Page 594 and 595:
578 IN VITRO VALIDATION AND ORAL FO
- Page 596 and 597:
580 IN VITRO VALIDATION AND ORAL FO
- Page 598 and 599:
582 IN VITRO VALIDATION AND ORAL FO
- Page 600 and 601:
584 IN VITRO VALIDATION AND ORAL FO
- Page 602 and 603:
586 IN VITRO VALIDATION AND ORAL FO
- Page 604 and 605:
588 IN VITRO VALIDATION AND ORAL FO
- Page 606 and 607:
590 IN VITRO VALIDATION AND ORAL FO
- Page 608 and 609:
592 NASAL DELIVERY OF PEPTIDE AND N
- Page 610 and 611:
594 NASAL DELIVERY OF PEPTIDE AND N
- Page 612 and 613:
596 NASAL DELIVERY OF PEPTIDE AND N
- Page 614 and 615:
598 NASAL DELIVERY OF PEPTIDE AND N
- Page 616 and 617:
600 NASAL DELIVERY OF PEPTIDE AND N
- Page 618 and 619:
602 NASAL DELIVERY OF PEPTIDE AND N
- Page 620 and 621:
604 NASAL DELIVERY OF PEPTIDE AND N
- Page 622 and 623:
606 NASAL DELIVERY OF PEPTIDE AND N
- Page 624 and 625:
608 NASAL DELIVERY OF PEPTIDE AND N
- Page 626 and 627:
610 NASAL DELIVERY OF PEPTIDE AND N
- Page 628 and 629:
612 NASAL DELIVERY OF PEPTIDE AND N
- Page 630 and 631:
614 NASAL DELIVERY OF PEPTIDE AND N
- Page 632 and 633:
616 NASAL DELIVERY OF PEPTIDE AND N
- Page 634 and 635:
618 NASAL DELIVERY OF PEPTIDE AND N
- Page 636 and 637:
620 NASAL DELIVERY OF PEPTIDE AND N
- Page 638 and 639:
622 NASAL DELIVERY OF PEPTIDE AND N
- Page 640 and 641:
624 NASAL DELIVERY OF PEPTIDE AND N
- Page 642 and 643:
626 NASAL DELIVERY OF PEPTIDE AND N
- Page 644 and 645:
628 NASAL DELIVERY OF PEPTIDE AND N
- Page 646 and 647:
630 NASAL DELIVERY OF PEPTIDE AND N
- Page 648 and 649:
632 NASAL DELIVERY OF PEPTIDE AND N
- Page 650 and 651:
634 NASAL DELIVERY OF PEPTIDE AND N
- Page 652 and 653:
636 NASAL DELIVERY OF PEPTIDE AND N
- Page 654 and 655:
638 NASAL DELIVERY OF PEPTIDE AND N
- Page 656 and 657:
640 NASAL DELIVERY OF PEPTIDE AND N
- Page 658 and 659:
642 NASAL DELIVERY OF PEPTIDE AND N
- Page 660 and 661:
644 NASAL DELIVERY OF PEPTIDE AND N
- Page 662 and 663:
646 NASAL DELIVERY OF PEPTIDE AND N
- Page 664 and 665:
648 NASAL DELIVERY OF PEPTIDE AND N
- Page 666 and 667:
650 NASAL DELIVERY OF PEPTIDE AND N
- Page 668 and 669:
652 NASAL POWDER DRUG DELIVERY clea
- Page 670 and 671:
654 NASAL POWDER DRUG DELIVERY cohe
- Page 672 and 673:
656 NASAL POWDER DRUG DELIVERY comb
- Page 674 and 675:
658 NASAL POWDER DRUG DELIVERY Its
- Page 676 and 677:
660 NASAL POWDER DRUG DELIVERY stud
- Page 678 and 679:
662 NASAL POWDER DRUG DELIVERY Chit
- Page 680 and 681:
664 NASAL POWDER DRUG DELIVERY PLGA
- Page 682 and 683:
666 NASAL POWDER DRUG DELIVERY ties
- Page 684 and 685:
668 NASAL POWDER DRUG DELIVERY [124
- Page 686 and 687:
TABLE 1 Continued Powder Formulatio
- Page 688 and 689:
TABLE 1 Continued Powder Formulatio
- Page 690 and 691:
674 NASAL POWDER DRUG DELIVERY REFE
- Page 692 and 693:
676 NASAL POWDER DRUG DELIVERY Drug
- Page 694 and 695:
678 NASAL POWDER DRUG DELIVERY 72.
- Page 696 and 697:
680 NASAL POWDER DRUG DELIVERY 109.
- Page 699 and 700:
5.8 AEROSOL DRUG DELIVERY Michael H
- Page 701 and 702:
HUMAN RESPIRATORY TRACT AND AEROSOL
- Page 703 and 704:
5.8.3 THERAPEUTIC INDICATIONS FOR A
- Page 705 and 706:
AEROSOL DRUG DELIVERY DEVICES 689 n
- Page 707 and 708:
FIGURE 1 Schematic of MDI. METERED
- Page 709 and 710:
TABLE 2 Property METERED DOSE INHAL
- Page 711 and 712:
METERED DOSE INHALERS 695 is then c
- Page 713 and 714:
METERED DOSE INHALERS 697 the other
- Page 715 and 716:
METERED DOSE INHALERS 699 the Easib
- Page 717 and 718:
5.8.6.2 Size Reduction and Particle
- Page 719 and 720:
DRY POWDER INHALERS 703 recognized
- Page 721 and 722:
DRY POWDER INHALERS 705 Spinhaler f
- Page 723 and 724:
oken up into droplets by the jet to
- Page 725 and 726:
EMERGING TECHNOLOGIES 709 Mouthpiec
- Page 727 and 728:
capillary, the formulation is rapid
- Page 729 and 730:
REFERENCES 713 22. Kim , C. S. , an
- Page 731 and 732:
REFERENCES 715 61. Blanchard , J. D
- Page 733 and 734:
REFERENCES 717 100. Dolovich , M. B
- Page 735 and 736:
REFERENCES 719 136. Anonymous ( 200
- Page 737 and 738:
REFERENCES 721 170. Ward , G. H. ,
- Page 739 and 740:
REFERENCES 723 206. Young , P. M. ,
- Page 741 and 742:
REFERENCES 725 244. DeFronzo , R. A
- Page 743:
REFERENCES 727 280. Schurmann , W.
- Page 746 and 747:
730 OCULAR DRUG DELIVERY tissues. T
- Page 748 and 749:
732 OCULAR DRUG DELIVERY FIGURE 3 S
- Page 750 and 751:
734 OCULAR DRUG DELIVERY melanocyte
- Page 752 and 753:
736 OCULAR DRUG DELIVERY represents
- Page 754 and 755:
738 OCULAR DRUG DELIVERY TABLE 1 Su
- Page 756 and 757:
740 OCULAR DRUG DELIVERY TABLE 1 Co
- Page 758 and 759:
742 OCULAR DRUG DELIVERY TABLE 2 Ma
- Page 760 and 761:
744 OCULAR DRUG DELIVERY shear - th
- Page 762 and 763:
746 OCULAR DRUG DELIVERY 5.9.3.3 Co
- Page 764 and 765:
748 OCULAR DRUG DELIVERY tigated in
- Page 766 and 767:
750 OCULAR DRUG DELIVERY that w/o M
- Page 768 and 769:
752 OCULAR DRUG DELIVERY [138, 232]
- Page 770 and 771:
754 OCULAR DRUG DELIVERY Only a few
- Page 772 and 773:
756 OCULAR DRUG DELIVERY 32. Schoen
- Page 774 and 775:
758 OCULAR DRUG DELIVERY 70. Shibuy
- Page 776 and 777:
760 OCULAR DRUG DELIVERY 105. Diepo
- Page 778 and 779:
762 OCULAR DRUG DELIVERY 139. Maest
- Page 780 and 781:
764 OCULAR DRUG DELIVERY 175. Davie
- Page 782 and 783:
766 OCULAR DRUG DELIVERY 213. Law ,
- Page 785 and 786:
5.10 MICROEMULSIONS AS DRUG DELIVER
- Page 787 and 788:
STRUCTURE AND FORMATION OF MICROEMU
- Page 789 and 790:
oily phase, and the interfacial lay
- Page 791 and 792:
CHARACTERIZE MICROEMULSIONS AND REL
- Page 793 and 794:
CHARACTERIZE MICROEMULSIONS AND REL
- Page 795 and 796:
study was conducted on systems comp
- Page 797 and 798:
5.10.6.1 Oral Drug Delivery MICROEM
- Page 799 and 800:
MICROEMULSIONS AS DRUG DELIVERY SYS
- Page 801 and 802:
REFERENCES 785 stability of incorpo
- Page 803 and 804:
REFERENCES 787 22. Saint - Ruth , H
- Page 805 and 806:
REFERENCES 789 58. Ktistis , G. ( 1
- Page 807 and 808:
REFERENCES 791 94. Rhee , Y. S. , C
- Page 809 and 810:
5.11 TRANSDERMAL DRUG DELIVERY C. S
- Page 811 and 812:
Drug plasma concentration FIGURE 1
- Page 813 and 814:
PHYSIOLOGY AND CHARACTERISTICS OF H
- Page 815 and 816:
Another important parameter when se
- Page 817 and 818:
COMMERCIALLY AVAILABLE PATCHES 801
- Page 819 and 820:
5.11.8.1 Chemical Penetration Enhan
- Page 821 and 822:
corneum much like the microneedle t
- Page 823:
REFERENCES 807 40. Mitragotri , S.
- Page 826 and 827:
810 VAGINAL DRUG DELIVERY 5.12.5.6
- Page 828 and 829:
812 VAGINAL DRUG DELIVERY The vagin
- Page 830 and 831:
814 VAGINAL DRUG DELIVERY have mucu
- Page 832 and 833:
816 VAGINAL DRUG DELIVERY TABLE 1 C
- Page 834 and 835:
818 VAGINAL DRUG DELIVERY Menopausa
- Page 836 and 837:
820 VAGINAL DRUG DELIVERY 500 400 3
- Page 838 and 839:
822 VAGINAL DRUG DELIVERY spreadabi
- Page 840 and 841:
824 VAGINAL DRUG DELIVERY distribut
- Page 842 and 843:
826 VAGINAL DRUG DELIVERY improved
- Page 844 and 845:
828 VAGINAL DRUG DELIVERY FIGURE 4
- Page 846 and 847:
830 VAGINAL DRUG DELIVERY FIGURE 6
- Page 848 and 849:
832 VAGINAL DRUG DELIVERY 5.12.4.10
- Page 850 and 851:
834 VAGINAL DRUG DELIVERY availabil
- Page 852 and 853:
836 VAGINAL DRUG DELIVERY 5.12.4.12
- Page 854 and 855:
838 VAGINAL DRUG DELIVERY results.
- Page 856 and 857:
840 VAGINAL DRUG DELIVERY 5.12.5.6
- Page 858 and 859:
842 VAGINAL DRUG DELIVERY studies t
- Page 860 and 861:
844 VAGINAL DRUG DELIVERY subject i
- Page 862 and 863:
846 VAGINAL DRUG DELIVERY formulati
- Page 864 and 865:
848 VAGINAL DRUG DELIVERY FIGURE 8
- Page 866 and 867:
850 VAGINAL DRUG DELIVERY shown to
- Page 868 and 869:
852 VAGINAL DRUG DELIVERY poloxamer
- Page 870 and 871:
854 VAGINAL DRUG DELIVERY made. Ide
- Page 872 and 873:
856 VAGINAL DRUG DELIVERY FIGURE 9
- Page 874 and 875:
858 VAGINAL DRUG DELIVERY 13. Wagne
- Page 876 and 877:
860 VAGINAL DRUG DELIVERY 54. Corbo
- Page 878 and 879:
862 VAGINAL DRUG DELIVERY supposito
- Page 880 and 881:
864 VAGINAL DRUG DELIVERY 123. van
- Page 882 and 883:
866 VAGINAL DRUG DELIVERY nanospher
- Page 884 and 885:
868 VAGINAL DRUG DELIVERY 196. Jone
- Page 886 and 887:
870 VAGINAL DRUG DELIVERY Irritatio
- Page 888 and 889:
872 VAGINAL DRUG DELIVERY 261. Czei
- Page 890 and 891:
874 VAGINAL DRUG DELIVERY 293. Fowl
- Page 892 and 893:
876 VAGINAL DRUG DELIVERY 327. O
- Page 894 and 895:
878 VAGINAL DRUG DELIVERY 359. Rath
- Page 897 and 898:
6.1 PHARMACEUTICAL PREFORMULATION:
- Page 899 and 900:
tion. According to global Internati
- Page 901 and 902:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 903 and 904:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 905 and 906:
TABLE 4 Disintegrant Starch Commonl
- Page 907 and 908:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 909 and 910:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 911 and 912:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 913 and 914:
DRUG-EXCIPIENT COMPATIBILITY 897 ap
- Page 915 and 916:
DRUG-EXCIPIENT COMPATIBILITY 899 in
- Page 917 and 918:
POWDER CHARACTERISTICS 901 their im
- Page 919 and 920:
POWDER CHARACTERISTICS 903 TABLE 13
- Page 921 and 922:
POWDER CHARACTERISTICS 905 Microsco
- Page 923 and 924:
Powder flow rate FIGURE 6 No flow b
- Page 925 and 926:
POWDER CHARACTERISTICS 909 Measurem
- Page 927 and 928:
V − V ε= V b p b V = 1− V POWD
- Page 929 and 930:
POWDER CHARACTERISTICS 913 The mois
- Page 931 and 932:
Tensile strength (Pa) 14 12 10 8 6
- Page 933 and 934:
POWDER CHARACTERISTICS 917 and poor
- Page 935 and 936:
infl uence the physicochemical prop
- Page 937 and 938:
Tablet disintegration is the import
- Page 939 and 940:
ability studies and from human stud
- Page 941 and 942:
Variables Affecting Dissolution In
- Page 943 and 944:
TABLET CHARACTERIZATION 927 The dif
- Page 945 and 946:
The requirements for content unifor
- Page 947:
REFERENCES 931 15. Simon , P. , Vev
- Page 950 and 951:
934 ROLE OF PREFORMULATION IN DEVEL
- Page 952 and 953:
936 ROLE OF PREFORMULATION IN DEVEL
- Page 954 and 955:
938 ROLE OF PREFORMULATION IN DEVEL
- Page 956 and 957:
940 ROLE OF PREFORMULATION IN DEVEL
- Page 958 and 959:
942 ROLE OF PREFORMULATION IN DEVEL
- Page 960 and 961:
944 ROLE OF PREFORMULATION IN DEVEL
- Page 962 and 963:
946 ROLE OF PREFORMULATION IN DEVEL
- Page 964 and 965:
948 ROLE OF PREFORMULATION IN DEVEL
- Page 966 and 967:
950 ROLE OF PREFORMULATION IN DEVEL
- Page 968 and 969:
952 ROLE OF PREFORMULATION IN DEVEL
- Page 970 and 971:
954 ROLE OF PREFORMULATION IN DEVEL
- Page 972 and 973:
956 ROLE OF PREFORMULATION IN DEVEL
- Page 974 and 975:
958 ROLE OF PREFORMULATION IN DEVEL
- Page 976 and 977:
960 ROLE OF PREFORMULATION IN DEVEL
- Page 978 and 979:
962 ROLE OF PREFORMULATION IN DEVEL
- Page 980 and 981:
964 ROLE OF PREFORMULATION IN DEVEL
- Page 982 and 983:
966 ROLE OF PREFORMULATION IN DEVEL
- Page 984 and 985:
968 ROLE OF PREFORMULATION IN DEVEL
- Page 986 and 987:
970 ROLE OF PREFORMULATION IN DEVEL
- Page 988 and 989:
972 ROLE OF PREFORMULATION IN DEVEL
- Page 990 and 991:
974 ROLE OF PREFORMULATION IN DEVEL
- Page 993 and 994:
6.3 TABLET DESIGN Eddy Castellanos
- Page 995 and 996:
TABLETING CYCLE 979 The eccentric p
- Page 997 and 998:
FIGURE 4 (a) (b) (c) TABLETING CYCL
- Page 999 and 1000:
TABLE 1 mm 3 4 5 6 7 8 9 10 11 12 1
- Page 1001 and 1002:
LIMITATIONS FOR DIRECT COMPRESSION
- Page 1003 and 1004:
Drug release (%) 120 100 80 60 40 2
- Page 1005 and 1006:
Beta Carotene Tablets (15 mg ) Form
- Page 1007 and 1008:
Lisinopril release (%) FIGURE 10 BI
- Page 1009 and 1010:
that do not compress well after wet
- Page 1011 and 1012:
Calcium phosphate, dibasic offers h
- Page 1013 and 1014:
FIGURE 11 Theophylline release (%)
- Page 1015 and 1016:
TABLET DESIGN WITH NATURAL PRODUCTS
- Page 1017 and 1018:
TABLE 7 Two Formulations for mangif
- Page 1019 and 1020:
TABLE 8 Weight Assay Disintegration
- Page 1021 and 1022:
TABLET DESIGN WITH NATURAL PRODUCTS
- Page 1023 and 1024:
has a regulatory effect upon the an
- Page 1025 and 1026:
DESIGN TOOLS OF TABLET FORMULATION
- Page 1027 and 1028:
Amount released PPL (%) 110 100 90
- Page 1029 and 1030:
DESIGN TOOLS OF TABLET FORMULATION
- Page 1031 and 1032:
Percolation threshold (ε c) FIGURE
- Page 1033 and 1034:
6.3.8 COATING SYSTEMS COATING SYSTE
- Page 1035 and 1036:
COATING SYSTEMS 1019 ences between
- Page 1037 and 1038:
Water absorption, % 8 7 6 5 4 3 2 1
- Page 1039 and 1040:
FIGURE 28 white. mg/h·m 0.9 0.8 0.
- Page 1041 and 1042:
(a) (b) FIGURE 31 ( a ) Tablet coat
- Page 1043 and 1044:
TABLE 18 Solid content Batch size,
- Page 1045 and 1046:
Percent released FIGURE 35 Tablet b
- Page 1047 and 1048:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1049 and 1050:
TABLE 23 Calculation of Tablet Prop
- Page 1051 and 1052:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1053 and 1054:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1055 and 1056:
TABLE 25 Aspect Ratios and Exponent
- Page 1057 and 1058:
K H (%min - 1/2)/% v/v excipient pl
- Page 1059 and 1060:
6.3.10 ULTRASOUND-ASSISTED TABLETIN
- Page 1061 and 1062:
ULTRASOUND-ASSISTED TABLETING (A NE
- Page 1063 and 1064:
REFERENCES 1047 18. S á nchez , G.
- Page 1065 and 1066:
REFERENCES 1049 54. Hess , H. , and
- Page 1067:
92. Mill á n , M. , and Caraballo
- Page 1070 and 1071:
1054 TABLET PRODUCTION SYSTEMS 6.4.
- Page 1072 and 1073:
1056 TABLET PRODUCTION SYSTEMS comp
- Page 1074 and 1075:
1058 TABLET PRODUCTION SYSTEMS and
- Page 1076 and 1077:
1060 TABLET PRODUCTION SYSTEMS FIGU
- Page 1078 and 1079:
1062 TABLET PRODUCTION SYSTEMS FIGU
- Page 1080 and 1081:
1064 TABLET PRODUCTION SYSTEMS FIGU
- Page 1082 and 1083:
1066 TABLET PRODUCTION SYSTEMS when
- Page 1084 and 1085:
1068 TABLET PRODUCTION SYSTEMS die
- Page 1086 and 1087:
1070 TABLET PRODUCTION SYSTEMS FIGU
- Page 1088 and 1089:
1072 TABLET PRODUCTION SYSTEMS TABL
- Page 1090 and 1091:
1074 TABLET PRODUCTION SYSTEMS Pres
- Page 1092 and 1093:
1076 TABLET PRODUCTION SYSTEMS Forc
- Page 1094 and 1095:
1078 TABLET PRODUCTION SYSTEMS In(1
- Page 1096 and 1097:
1080 TABLET PRODUCTION SYSTEMS In[1
- Page 1098 and 1099:
1082 TABLET PRODUCTION SYSTEMS [78,
- Page 1100 and 1101:
1084 TABLET PRODUCTION SYSTEMS FIGU
- Page 1102 and 1103:
1086 TABLET PRODUCTION SYSTEMS When
- Page 1104 and 1105:
1088 TABLET PRODUCTION SYSTEMS 3. P
- Page 1106 and 1107:
1090 TABLET PRODUCTION SYSTEMS 44.
- Page 1108 and 1109:
1092 TABLET PRODUCTION SYSTEMS 81.
- Page 1110 and 1111:
1094 TABLET PRODUCTION SYSTEMS 119.
- Page 1112 and 1113:
1096 TABLET PRODUCTION SYSTEMS 160.
- Page 1114 and 1115:
1098 TABLET PRODUCTION SYSTEMS 197.
- Page 1116 and 1117:
1100 CONTROLLED RELEASE OF DRUGS FR
- Page 1118 and 1119:
1102 CONTROLLED RELEASE OF DRUGS FR
- Page 1120 and 1121:
1104 CONTROLLED RELEASE OF DRUGS FR
- Page 1122 and 1123:
1106 CONTROLLED RELEASE OF DRUGS FR
- Page 1124 and 1125:
1108 CONTROLLED RELEASE OF DRUGS FR
- Page 1126 and 1127:
1110 CONTROLLED RELEASE OF DRUGS FR
- Page 1128 and 1129:
1112 CONTROLLED RELEASE OF DRUGS FR
- Page 1130 and 1131:
1114 CONTROLLED RELEASE OF DRUGS FR
- Page 1132 and 1133:
1116 CONTROLLED RELEASE OF DRUGS FR
- Page 1134 and 1135:
1118 CONTROLLED RELEASE OF DRUGS FR
- Page 1136 and 1137:
1120 CONTROLLED RELEASE OF DRUGS FR
- Page 1138 and 1139:
1122 CONTROLLED RELEASE OF DRUGS FR
- Page 1140 and 1141:
1124 CONTROLLED RELEASE OF DRUGS FR
- Page 1142 and 1143:
1126 CONTROLLED RELEASE OF DRUGS FR
- Page 1144 and 1145:
1128 CONTROLLED RELEASE OF DRUGS FR
- Page 1146 and 1147:
1130 CONTROLLED RELEASE OF DRUGS FR
- Page 1148 and 1149:
1132 CONTROLLED RELEASE OF DRUGS FR
- Page 1150 and 1151:
1134 TABLET COMPRESSION stages invo
- Page 1152 and 1153:
1136 TABLET COMPRESSION although on
- Page 1154 and 1155:
1138 TABLET COMPRESSION P P = + C a
- Page 1156 and 1157:
1140 TABLET COMPRESSION 4. Estimati
- Page 1158 and 1159:
1142 TABLET COMPRESSION from a hopp
- Page 1160 and 1161:
1144 TABLET COMPRESSION speed of th
- Page 1162 and 1163:
1146 TABLET COMPRESSION FIGURE 4 Co
- Page 1164 and 1165:
1148 TABLET COMPRESSION FIGURE 5 Id
- Page 1166 and 1167:
1150 TABLET COMPRESSION its low tou
- Page 1168 and 1169:
1152 TABLET COMPRESSION Standard TS
- Page 1170 and 1171:
1154 TABLET COMPRESSION A B C D E F
- Page 1172 and 1173:
1156 TABLET COMPRESSION Top view Pr
- Page 1174 and 1175:
1158 TABLET COMPRESSION particle si
- Page 1176 and 1177:
1160 TABLET COMPRESSION 6.6.10.3 Mo
- Page 1178 and 1179:
1162 TABLET COMPRESSION 7. Masteau
- Page 1181 and 1182:
6.7 EFFECTS OF GRINDING IN PHARMACE
- Page 1183 and 1184:
MILLING EQUIPMENT 1167 whereas smal
- Page 1185 and 1186:
Screen Product FIGURE 3 Hammers Ham
- Page 1187 and 1188:
inders, disintegrants, glidants, lu
- Page 1189 and 1190:
Airflow Press POWDER CHARACTERIZATI
- Page 1191 and 1192:
Powder flow Sample Process stream (
- Page 1193 and 1194:
Container 1 Container 1 Discard (a)
- Page 1195 and 1196:
Porous particles in container POWDE
- Page 1197 and 1198:
POWDER CHARACTERIZATION TECHNIQUES
- Page 1199 and 1200:
expansions or fractal dimensions);
- Page 1201 and 1202:
EFFECT OF PARTICLE SIZE REDUCTION O
- Page 1203 and 1204:
EFFECT OF PARTICLE SIZE REDUCTION O
- Page 1205 and 1206:
REFERENCES 1189 19. British Standar
- Page 1207 and 1208:
6.8 ORAL EXTENDED - RELEASE FORMULA
- Page 1209 and 1210:
INTRODUCTION 1193 line) together wi
- Page 1211 and 1212:
INTRODUCTION 1195 substance) instea
- Page 1213 and 1214:
of the drug particles/formulation a
- Page 1215 and 1216:
M A DCt t = ⎡ ε s ( 2C − C )
- Page 1217 and 1218:
method for insoluble matrix tablets
- Page 1219 and 1220:
MEMBRANE-COATED ORAL EXTENDED RELEA
- Page 1221 and 1222:
MEMBRANE-COATED ORAL EXTENDED RELEA
- Page 1223 and 1224:
Swelling front Diffusion front Eros
- Page 1225 and 1226:
dM Q = ∫ dt = kt 0 dt HYDROPHILIC
- Page 1227 and 1228:
TABLE 2 FDA Registered Oral ER Form
- Page 1229 and 1230:
6.8.6 OTHER ORAL ER FORMULATIONS OT
- Page 1231 and 1232:
REFERENCES 1215 15. Neau , S. H. ,
- Page 1233 and 1234:
REFERENCES 1217 54. Sousa , J. J. ,
- Page 1235 and 1236:
REFERENCES 1219 89. Ford , J. L. ,
- Page 1237 and 1238:
REFERENCES 1221 122. Talukdar , M.
- Page 1239:
SECTION 7 ROLE OF NANOTECHNOLOGY
- Page 1242 and 1243:
1226 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1244 and 1245:
1228 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1246 and 1247:
1230 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1248 and 1249:
1232 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1250 and 1251:
1234 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1252 and 1253:
1236 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1254 and 1255:
1238 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1256 and 1257:
1240 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1258 and 1259:
1242 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1260 and 1261:
1244 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1262 and 1263:
1246 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1265 and 1266:
7.2 NANOTECHNOLOGY IN PHARMACEUTICA
- Page 1267 and 1268:
NANOMATERIALS 1251 tists regard mat
- Page 1269 and 1270:
NANOMATERIALS 1253 TABLE 1 Characte
- Page 1271 and 1272:
NANOMATERIALS 1255 sor molecules/pa
- Page 1273 and 1274:
TABLE 2 Continued Types of Nanomate
- Page 1275 and 1276:
H 3 C CH 3 N + CH 3 O O O O - P O O
- Page 1277 and 1278:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1279 and 1280:
entrapped drugs releasing [90] . So
- Page 1281 and 1282:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1283 and 1284:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1285 and 1286:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1287 and 1288:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1289 and 1290:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1291 and 1292:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1293 and 1294:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1295 and 1296:
NANOMEDICINE 1279 prises) visibly p
- Page 1297 and 1298:
REFERENCES 1281 16. http://www.whit
- Page 1299 and 1300:
REFERENCES 1283 55. Kam , N. W. S.
- Page 1301 and 1302:
REFERENCES 1285 92. Zhang , J. Q. ,
- Page 1303 and 1304:
REFERENCES 1287 126. Smart , S. K.
- Page 1305 and 1306:
7.3 PHARMACEUTICAL NANOSYSTEMS: MAN
- Page 1307 and 1308:
7.3.2 TAXONOMY OF NANOMEDICINE TECH
- Page 1309 and 1310:
TABLE 1 Continued Molecular medicin
- Page 1311 and 1312:
Applications of quantum dots includ
- Page 1313 and 1314:
7.3.5 MANUFACTURING TECHNOLOGIES Th
- Page 1315 and 1316:
Ratio of hydrodynamic radius, R H ,
- Page 1317 and 1318:
eplicated on the substrate, with na
- Page 1319 and 1320:
MANUFACTURING TECHNOLOGIES 1303 bel
- Page 1321 and 1322:
CHARACTERIZATION TECHNIQUES 1305 TA
- Page 1323 and 1324:
CHARACTERIZATION TECHNIQUES 1307 TA
- Page 1325 and 1326:
Limitations of AFM [255 - 257] Pote
- Page 1327 and 1328:
REFERENCES 1311 thelial cells, the
- Page 1329 and 1330:
REFERENCES 1313 34. Ostrander , K.
- Page 1331 and 1332:
REFERENCES 1315 77. Muangsiri , W.
- Page 1333 and 1334:
REFERENCES 1317 124. Caruso , F. ,
- Page 1335 and 1336:
REFERENCES 1319 170. Rogers , J. A.
- Page 1337 and 1338:
REFERENCES 1321 application: Synthe
- Page 1339 and 1340:
252. Fontaine , P. A. , et al. ( 19
- Page 1341:
Characterization Methods Binks , B.
- Page 1344 and 1345:
1328 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1346 and 1347:
1330 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1348 and 1349:
1332 Application TABLE 1 Selected M
- Page 1350 and 1351:
1334 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1352 and 1353:
1336 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1354 and 1355:
1338 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1356 and 1357:
1340 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1358 and 1359:
1342 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1360 and 1361:
1344 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1362 and 1363:
1346 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1364 and 1365:
1348 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1366 and 1367:
1350 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1368 and 1369:
1352 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1370 and 1371:
1354 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1372 and 1373:
1356 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1374 and 1375:
1358 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1376 and 1377:
1360 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1378 and 1379:
1362 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1380 and 1381:
1364 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1382 and 1383:
1366 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1384 and 1385:
1368 INDEX Cholera toxin, 637 Cilio
- Page 1386:
1370 INDEX Production of radiopharm